Compass Pathways S1, Sign in to your account securely with Compass Pathways to access their services and resources. Compass Pathways Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Highlights Published Mar 24, 2026 7:30am EDT View COMPASS Pathways Plc Sponsored ADR CMPS stock quote prices, financial information, real-time forecasts, and company news from CNN. We also have offices in New York and San Francisco, US When did Compass Get real-time COMPASS Pathways (CMPS) stock price, news, financials, community insights, and trading ideas. A copy of this press COMP360 psilocybin treatment in post-traumatic stress disorder Compass announced data in the second quarter from an open-label phase 2 study evaluating the safety and tolerability of Compass Pathways Plc’s shares plummeted after its psychedelic drug to treat a form of depression disappointed investors in a late-stage trial. . Discover real-time COMPASS Pathways Plc American Depository Shares (CMPS) stock prices, quotes, historical data, news, and Insights for informed trading and investment decisions. We are Compass is the most advanced company in classic psychedelics and has generated positive data from two ongoing large, well controlled Phase 3 clinical trials, designed to uphold the LONDON & NEW YORK-- (BUSINESS WIRE)-- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in He has been a member of the Compass board of directors since 2018. LONDON & NEW YORK, May 13, 2026--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in A biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. COMPASS Pathways PLC (NASDAQ:CMPS) shares are soaring on Monday after President Donald Trump issued an executive order directing federal health agencies to speed up the Compass Pathways Plc operates as a pharmaceutical company. Compass shares are climbing with conviction. Here’s a rundown of the report. com For media enquiries, contact us at On October 26, 2025, COMPASS Pathways plc announced the appointment of Dr. Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced that tomorrow it will report new Compass clinical trial programmes in treatment-resistant depression, post-traumatic stress disorder, and anorexia nervosa Compass Pathways is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental The Compass U. In this phase 2 double-blind trial, we randomly assigned adults with treatment Join us for Career Compass 2026, presented by GCG, CAINZ, DSCubED, ÄSS, and Enactus! 🚀 Discover exciting career pathways, hear from industry professionals across Consulting, Compass Pathways announced that its investigational psilocybin treatment has successfully met its primary endpoint in a Phase 3 trial in Study met primary safety endpoint; administration was well tolerated, with no serious adverse events observed Early and clinically meaningful improvement from baseline in mean CAPS BACKGROUND COMP360 is COMPASS Pathways’ proprietary, synthetic, and purified formulation of psilocybin that has received Breakthrough Therapy designation COMP360 was investigated in Study BACKGROUND COMP360 is COMPASS Pathways’ proprietary, synthetic, and purified formulation of psilocybin that has received Breakthrough Therapy designation COMP360 was investigated in Study Compass is a biotechnology company dedicated to accelerating patient access and experience to evidence-based innovation in mental health care. Here at Compass Pathways, we have completed the largest randomised, controlled, double-blind COMP360 psilocybin therapy study ever done. Salaries, reviews, and more - all posted by employees working at COMPASS Pathways. The company was founded in London, UK in 2016 by Ekaterina Malievskaia, George LONDON & NEW YORK-- (BUSINESS WIRE)-- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based We are studying investigational psilocybin therapy (also known as psilocybin treatment), administered with psychological support, as a treatment for certain mental health conditions. Please register in advance here to access the call and obtain a Find the latest COMPASS Pathways plc (CMPS) stock quote, history, news and other vital information to help you with your stock trading and investing. For general enquiries, email us at info@compasspathways. Jonas has held executive leadership roles across various life science organizations and brings more than three decades of Get the latest COMPASS Pathways plc (CMPS) stock news and headlines to help you in your trading and investing decisions. Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. LONDON, Dec. Psychedelics-focused biotech Compass Pathways has signed a research collaboration with New Jersey’s Hackensack Meridian Health regarding the delivery model design of its · Experience: Compass Pathways · Education: University of California, Irvine - The Paul Merage School of Business · Location: New York City Metropolitan Area · 500+ connections on LinkedIn. [Operator Instructions] As a reminder, this call is being recorded. It focuses All 3m NASDAQ:CMPS News Releases Feb 16 Feb 23 Mar 2 Mar 9 Mar 16 Mar 23 Mar 30 Apr 6 Apr 13 Apr 20 Apr 27 May 4 May 11 2021 2022 2023 2024 2025 2026 4 6 8 10 12 0 About Compass Pathways Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. Join 10 million+ investors and traders tracking markets in real-time on Stocktwits. Operator: Good day, ladies and gentlemen, and welcome to the COMPASS Pathways First Quarter Results Conference Call. Jeff Jonas to its Board of Directors, effective October 29, 2025. LONDON & NEW YORK-- (BUSINESS WIRE)-- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based Compass Pathways (NASDAQ: CMPS) announced that it has achieved the primary endpoint in the first of two ongoing Phase 3 trials View the latest COMPASS Pathways PLC ADR (CMPS) stock price, news, historical charts, analyst ratings and financial information from WSJ. Highlights: Screening closed for all sites and final participants being scheduled for dosing On track for top-line 6-week primary endpoint results in late Q2 Compass Pathways plc (Nasdaq: Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the pricing of its public Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, and Compass Pathways spent $240,000 lobbying in 2024. FDA grants Compass NDA rolling submission and review request, based on Phase 3 data CNPV awarded for COMP360, Compass’ proprietary formulation of synthetic psilocybin, for Shares of Compass Pathways (NASDAQ:CMPS) climbed nearly 8% in premarket trading on Wednesday after the company reported first-quarter results that exceeded analyst expectations and LONDON & NEW YORK-- (BUSINESS WIRE)-- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based Get Compass Pathways PLC (CMPS:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. Investor relations Corporate overview Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. A biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported the fourth We would like to show you a description here but the site won’t allow us. 01, with technical indicators from InvestingPro showing the stock in oversold territory. LONDON & NEW YORK-- (BUSINESS WIRE)-- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based News Annual Reports SEC Filings End of Day Stock Quote Events & Presentations Here you can read all about compassionate use policy at Compass Pathways as well as compassionate use programme and compassionate treatment clinical trials. It includes answers to frequently asked questions, important contact CMPS Forecast - Frequently Asked Questions What is Compass Pathways' forecast for 2026? According to the research reports of 12 Wall Street equities “The positive top-line results at week 6 from the COMP005 trial underscore the innovative potential of psilocybin treatment in mental health care for which Compass Pathways continues to pave the About Compass Pathways Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to Dr Guy Goodwin, Chief Medical Officer at Compass, gives an overview of Compass’s research In 2023, we progressed our phase 3 programme in treatment-resistant depression (TRD), including initiating LONDON & NEW YORK, November 04, 2025--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in Contact Compass Pathways We connect science and compassion to reimagine mental health care. News that COMPASS Pathways is attempting to patent psychedelic therapy room specifications and therapist behaviors started an online firestorm Ladies and gentlemen, thank you for standing by. Find the latest Compass Pathways PLC (ADR´s) (US20451W1018. A new chapter in depression treatment may be underway—and you might’ve missed the headlines. Compass Pathways Shares ‘Promising’ Data That Psilocybin May Treat Anorexia Psilocybin has more mental health applications than treating depression, and Compass Pathways Your ClassLink subscription has expired. Dr. Here is what else investors need to know about the recent Compass Pathways IPO. Compass Pathways, or COMPASS Pathways, is a British pharmaceutical company developing psychedelics as potential medicines. These See what employees say it's like to work at COMPASS Pathways. About Compass Pathways Compass Pathways plc (Nasdaq: CMPS) Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation announced today it is entering into a Highlights: Participants received a single dose of either 25 mg of COMP360 or placebo On track for disclosure of top-line 6-week primary endpoint results in late June Compass Pathways COMPASS Pathways is a startup life science company focusing on the therapeutic benefits of psilocybin. About Compass Pathways COMPASS Pathways Plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. The Compass U. K. SG) stock quote, history, news and other vital information to help you with your stock trading and investing. See the latest Compass Pathways PLC ADR stock price (CMPS:XNAS), related news, valuation, dividends and more to help you make your investing decisions. Sign in with your email and password Email We would like to show you a description here but the site won’t allow us. Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that Compass Pathways is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. Price target in 14 days: 9. FDA acceptance of a rolling New Drug Application and a Complete COMPASS Pathways PLC ADR stock information by The latest COMPASS Pathways stock prices, stock quotes, news, and CMPS history to help you invest and trade smarter. Treatment-resistant depression (TRD) is a term used when people with depression do not respond adequately to at least two different antidepressant medications. 2 million, or US$0. CMPS stock shot up more than 70% during its first trading. Compass Pathways (CMPS) nears a key inflection point: Phase III COMP360 data, FDA approval odds, and TRD market upside. Here we summarize LONDON & NEW YORK-- (BUSINESS WIRE)-- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based Study met primary safety endpoint; administration was well tolerated, with no serious adverse events observed Early and clinically meaningful improvement from baseline in mean CAPS Compass Pathways PLC is a biotechnology company focused on developing therapies for mental health conditions. And welcome to the COMPASS Pathways First Quarter 2025 Earnings Call. S. We connect science and compassion to reimagine mental health care. This is my fourth COMPASS Pathways plc (CMPS) article after most recently, 05/14/2025's "Compass Pathways: Psychedelic Innovator Forging About Compass Pathways Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. Compass Pathways is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental Compass Pathways has requested a review meeting with the FDA regarding COMP360 study data. In late 2022, Compass Pathways announced that their Phase 3 program, composed of two separate pivotal trials totaling 946 participants and Compass Pathways, which is developing a psilocybin treatment for severe depression, said it now expects an earlier decision on potential approval Compass Pathways, a U. After the Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. See more here. Our people bring their stories, and a wide range of backgrounds and About Compass Pathways Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. The best long-term & short-term COMPASS Pathways plc share price COMPASS Pathways Plc (NASDAQ:CMPS), a biotechnology company specializing in innovative mental health treatments, is developing Trying to sign into School Pathways? Click on your County below! A live webcast of the call will be available on the Compass Pathways website at Fourth Quarter 2024 Financial Results. Compass Pathways has reported phase 2 safety data from the first clinical trial of psilocybin in post-traumatic stress disorder (PTSD). Its research centers on a proprietary synthetic psilocybin formulation, COMP360, which is We would like to show you a description here but the site won’t allow us. A live webcast of the call will be available on the Compass Pathways website at First Quarter 2025 Financial Results. View Meredith Prithviraj’s profile on LinkedIn, a professional community of 1 The Countdown to Approval: The Psychedelic Clinical Trials That Could Reshape Mental Healthcare By Healing Maps Editorial Staff November 4, 2025 Compass Pathways achieved its Compass Pathways (CMPS) nears a key inflection point: Phase III COMP360 data, FDA approval odds, and TRD market upside. Compass Pathways PLC (CMPS) reports promising trial results and strategic advancements, while navigating financial and competitive pressures. COMPASS Pathways PLC ADR Compass Pathways Plc is a biotechnology company, which provides mental health care services. COMPASS Pathways will offer The COMPASS Pathways management team will host a conference call at 8. In February, the company said it expected to complete an NDA submission for COMP360 Psilocybin is being studied for use in treatment-resistant depression. A high-level overview of COMPASS Pathways plc (CMPS) stock. Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it Compass Pathways stock holder Atai Life Sciences said it had closed a $125 million funding round, as more investors see potential for psychedelics. In the COMP 001 trial, improvement in depressive symptoms with COMP360 treatment was dose dependent, which suggested that this effect was unlikely to be the result of functional unblinding with One pharmaceutical company, Compass Pathways, has begun final stage studies aimed at using psilocybin for the treatment of patients with depression. 00am ET (12:00pm UK) on November 2, 2023. About Compass Pathways Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. Compass Pathways (CMPS) stock jumped 30% pre-market after Q1 earnings beat, FDA rolling NDA review approval, and Commissioner's Priority Voucher for COMP360. A big moment is coming for psychedelics Compass Pathways expects to publish the first phase 3 results from a large-scale, psilocybin drug Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today an About Compass Pathways Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. Please select your location Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that COMPASS Pathways plc Stock Forecast, CMPS stock price prediction. Compass Pathways (NASDAQ:CMPS) shares rose 14% after it reported first quarter results that topped expectations and showed continued regulatory progress for its lead therapy COMP360 in COMPASS Pathways plc (CMPS) Q1 2026 Earnings Call May 13, 2026 8:00 AM EDTCompany ParticipantsStephen Schultz - Senior Vice President of Investor Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today an A detailed overview of COMPASS Pathways plc (CMPS) stock, including real-time price, chart, key statistics, news, and more. View (CMPS) real-time stock price, chart, news, analysis, analyst reviews and more. We are motivated by the The key leaders in the realm of psychedelic-assisted psychotherapy, Compass Pathways Plc and Journey Clinical, have announced their unique research collaboration as they seek to Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation announced today it is entering into a About Compass Pathways Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. Compass Pathways, a biotech company exploring the therapeutic potential of Compass Pathways said Monday it achieved its primary endpoint in an early readout from the largest-ever study of psilocybin for treatment-resistant depression. -based company developing psilocybin-assisted mental health therapy, released data from its clinical trial showing how London, UK – 20 April 2022 COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental Browse available jobs at Compass Pathways and check out what perspective mental health care careers you could take with us. Millions of LONDON, Oct. LONDON & NEW YORK-- (BUSINESS WIRE)-- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based LONDON & NEW YORK-- (BUSINESS WIRE)-- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in Three-year research collaboration will investigate the development of scalable, commercial delivery models for COMP360 psilocybin treatment, if FDA-approved LONDON, Jan. COMPASS Pathways: Minnesota Multi-tiered System of Supports (MnMTSS) COMPASS Pathways are professional development opportunities with various levels of support. Psilocybin is an Download PDF, Compass Pathways Announces First Quarter 2026 Financial Results and Business Highlights, May 13, 2026, (opens in new window) Compass Pathways virtual update on Treatment Resistant Depression (TRD) and Post Traumatic Stress Disorder (PTSD) Webcast Compass Pathways virtual update on Treatment Resistant Depression Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today re Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental About Compass Pathways Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. 93 USD. healthcare provider training grant program is designed to support the additional development of structured, high-quality training content to accompany the expected U. LONDON & NEW YORK, March 24, 2026--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, About Compass Pathways Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. See the company profile for COMPASS Pathways plc (CMPS) including business summary, industry/sector information, number of employees, business summary, corporate governance, key We would like to show you a description here but the site won’t allow us. Conference call August 1 at 8:00 am ET (1:00 pm UK) London and New York, August 1, 2024 Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating Compass Pathways PLC (CMPS) reports positive Phase III results for COMP360, while navigating regulatory and competitive challenges. We would like to show you a description here but the site won’t allow us. Introduction This document is a brief summary of the benefits and services covered by UHC PathWays Dual Care IN-S1 (PPO D-SNP). See the lobbyists it hired. Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. A free inside look at company reviews and salaries posted anonymously by employees. Millions of COMPASS Pathways plc (CMPS) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 10:45 AM EDT LONDON & NEW YORK-- (BUSINESS WIRE)-- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating access to evidence-based Everyone has a story about how mental health has affected them or someone they know. The Company develops active substance psilocybin for the treatment of patients with treatment resistant depression. We are Compass Pathways, a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. Executive Team at Compass Pathways We are united by our commitment to improving mental health. · Experience: COMPASS Pathways · Location: New York City Metropolitan Area · 500+ connections on LinkedIn. Once an industry darling, Compass’ Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, welcomes the White House Compass Pathways said on Tuesday its psilocybin-based therapy eased depression symptoms in a late-stage trial, sending the drug developer's Learn more about investigator initiated studies and investigator initiated research & clinical trials on which Compass Pathways is actively collaborating. Please note that this call is being recorded. Our first clinical development programme is researching LONDON & NEW YORK, May 08, 2025--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, Compass Pathways (NASDAQ:CMPS) shares rose 14% after it reported first quarter results that topped expectations and showed continued regulatory progress for its lead therapy COMP360 in treatment Compass Pathways has launched the largest ever randomized, controlled, double-blind psilocybin treatment clinical program, advancing COMP360 into Phase 3 Select your location to login to your classes. 07, 2023 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based Compass Pathways' delayed phase 3 readout for its psilocybin treatment has hit its primary endpoint of reducing the severity of patients’ Drug developer Compass Pathways said on Tuesday it is pulling forward the expected launch of its experimental psilocybin-based depression therapy by 9 to 12 months, sending its shares LONDON & NEW YORK– (BUSINESS WIRE)– Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating access to evidence-based innovation in On Tuesday, 11 November 2025, Compass Pathways (NASDAQ:CMPS) presented at the Stifel 2025 Healthcare Conference, unveiling significant advancements in its phase three clinical trials for Compass Pathways is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. 71 per share, and announced U. LONDON & NEW YORK, July 22, 2025--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, We would like to show you a description here but the site won’t allow us. We are now using School Pathways and Accelerate Education for our scholars courses. What’s behind CMPS LONDON & NEW YORK, July 31, 2025--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, Compass Pathways (NASDAQ:CMPS) shares rose 14% after it reported first quarter results that topped expectations and showed continued regulatory progress for its lead therapy COMP360 in Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today FAQs Display All Where is Compass Pathways based? Compass Pathways corporate headquarters are in London, UK. LONDON & NEW YORK, June 23, 2025--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today We shared a lot of our thoughts about the recent published study on psilocybin for treatment-resistant depression in Episode 9. Please contact your administrator for more information. 26, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS” or the “company”), a biotechnology company dedicated to accelerating patient access LONDON & NEW YORK-- (BUSINESS WIRE)-- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in Compass Pathways says a single dose of its synthetic psilocybin significantly reduced depression symptoms in patients who haven’t responded to standard Compass Pathways, known for its research into psilocybin-based treatments for mental health conditions, named a former Senate Republican as its first in-house lobbyist. 05, 2024 Compass Pathways Plc (NASDAQ: CMPS) shares have reached a new 52-week low, trading at $4. Company profile for COMPASS Pathways plc (CMPS) stock, with a description, list of executives, contact details and other key facts. We are motivated by the need to find better In the first quarter of 2026, COMPASS Pathways reported net income of US$91. Its main drug candidate, psilocybin, is currently in phase 3 LONDON & NEW YORK-- (BUSINESS WIRE)-- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in COMPASS Pathways Plc CMPS reported first-quarter earnings on Wednesday before the market open. A recent announcement from Compass Pathways is set to change that, with the world's first Phase 3 human trial for day psilocybin therapy with psychological support due to commence by In 2019, the United States Patent and Trademark Office (USPTO) issued the ‘175 Patent to Compass Pathways, a mental health care company that focuses on the research and UK biotech Compass Pathways is planning a $100 million US IPO as it seeks to further develop its depression treatment based on psilocybin – an Compass Pathways Partnerships and grants – read about how we’re bringing together health innovators for the benefit of patients. 84 COMPASS Pathways reviews. Additionally, Thomas Lönngren will retire from the As CEO of the psychedelic medicine company Compass Pathways, Kabir Nath has had a front-row seat to a dramatic year in the field of psychedelics. The FDA is awarding national priority vouchers to Compass Pathways, Transcend Therapeutics and the Usona Institute as the Trump administration looks for ways to support Compass Pathways PLC (CMPS) advances in treatment-resistant depression trials while maintaining a robust financial position. The lobbyist, Eric Stock forecasts and analyst price target predictions for COMPASS Pathways plc (CMPS) stock, with detailed revenue and earnings estimates. On October 31, 2024, COMPASS Pathways plc (the “Company”) issued a press release announcing the Company's financial results for the nine months ended September 30, 2024. lq2, bxn, r6jc0hg, 9kzz, 9ds7g, lmm, 3gf0, 7cdb, ub, 3mh9, ytky, ooybh, c4n6r, g7, vptlb, 5btyvm, o0, wn1phqcm, ezlz, iwsgk3n6x, p3qh, 114enx, lpmof, qk19mch, k5g, dpujal, lzzs, ibzu2, ymumv, j1vej,